InterCure Ltd.
NASDAQ:INCR · NASDAQ Global Market
+$0.08 today
Vol 0.02M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.0%
avg -13.7%
ROIC
1.0%
avg -12.5%
ROA
-5.2%
avg -9.2%
Analysis
ROIC is currently the strongest return metric at 1.0% versus its period average of -12.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Amos Cohen | Chief Financial Officer | $1.29M | — | 47 | $79,947.00 | 0.15% |
Alexander Rabinovich | Chief Executive Officer & Chairman | $734,000.00 | — | 55 | $1.14M | 2.08% |
Einat Zehavi | Vice President of Sales | $678,000.00 | — | — | — | — |
Itai Kabiljo | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | -45.1% | +112.1% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -45.1% over three years. Forward estimates point to Revenue at +112.1% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Edap Tms S.a.
EDAP
$178.23M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$153.02M
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.86M
American Well Corporation
NYSE:AMWL
$145.20M
Cardiol Therapeutics Inc.
NASDAQ:CRDL
$121.04M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$95.01M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$84.11M
MindWalk Holdings Corp.
NASDAQ:HYFT
$72.87M
Biomea Fusion, Inc.
NASDAQ:BMEA
$71.40M
Who manages INCR?
InterCure Ltd. (INCR) lists 4 active executives. The top listed executive is Itai Kabiljo, General Counsel.
Are INCR insiders buying or selling?
Recent insider activity shows net selling of $138.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.